Epcoritamab-Bysp 4 mg/0.8 mL, 48 mg/0.8 mL Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 4 mg/0.8 mL, 48 mg/0.8 mL
Reference Brands: EPKINLY (USA)
Category: Oncology Cancer Care
Epcoritamab (brand name Epkinly) is a bispecific monoclonal antibody that binds to both CD3 on T-cells and CD20 on B-cells, redirecting T-cells to kill malignant B-cells. It is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Administered subcutaneously, Epkinly provides an off-the-shelf immunotherapy alternative to CAR-T treatments. The medicine is jointly developed and marketed by AbbVie and Genmab.
Epcoritamab-Bysp — third party manufacturing & bulk supply
Epcoritamab-Bysp 4 mg/0.8 mL, 48 mg/0.8 mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Epcoritamab-Bysp is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Epcoritamab-Bysp listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Epcoritamab-Bysp →Frequently Asked Questions
Epcoritamab-bysp is used for the treatment of adults with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma. It works by engaging the patient’s T-cells to target and destroy malignant B-cells, offering a targeted immunotherapy approach for aggressive lymphomas.
Epcoritamab-bysp is made from Epcoritamab-bysp, a bispecific humanized monoclonal antibody that binds both CD3 on T-cells and CD20 on B-cells to promote immune-mediated destruction of cancerous B-cells.
The trade name of Epcoritamab-bysp is Epkinly.
Epcoritamab-bysp (Epkinly) is developed and manufactured by Genmab and AbbVie and marketed under approved regulatory pathways for B-cell lymphoma.
The generic name of Epcoritamab-bysp is Epcoritamab-bysp.
The brand name of Epcoritamab-bysp is Epkinly.
Epcoritamab-bysp is manufactured in the United States and Europe by Genmab and AbbVie under strict GMP conditions for oncology therapeutics.
Related Products
Eribulin Mesylate
Strength:
0.44 mg/mL
Form: Injection
Reference Brands: HALAVEN (USA/EU)
View Details
Ixazomib Capsule
Strength:
2.3mg, 3mg, 4mg
Form: Capsules
Reference Brands: Ninlaro (US/EU)
View Details
Temozolomide 100 Mg Capsule
Strength:
Capsule( 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, 250 mg); Powder( 100 mg/vial)
Form: Capsule and Powder for reconstitution
Reference Brands: Temodar(US), Temodal (EU)
View Details
Thalidomide
Strength:
50 mg, 100 mg, 150 mg , 200 mg
Form: Capsules
Reference Brands: Thalomid®(US), Thalidomide Celgene(EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
